Insider · CIK 0001746830

Agarwal Shefali

Reports to the SEC for 3 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001746830

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-12	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+87.9K sh	—	—	87,900
2025-05-29	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+55K sh	—	—	55,000
2025-04-04	Gritstone bio, Inc.Stock Option (Right to Buy)J Other	Director	JOther	−38K sh	—	—	0
2025-04-04	Gritstone bio, Inc.Stock Option (Right to Buy)J Other	Director	JOther	−19K sh	—	—	0
2025-04-04	Gritstone bio, Inc.Stock Option (Right to Buy)J Other	Director	JOther	−51.8K sh	—	—	0
2025-04-04	Gritstone bio, Inc.Stock Option (Right to Buy)J Other	Director	JOther	−937 sh	—	—	0
2025-04-04	Gritstone bio, Inc.Stock Option (Right to Buy)J Other	Director	JOther	−51.8K sh	—	—	0
2024-06-17	Gritstone bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+51.8K sh	—	—	51,800
2024-06-07	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2023-06-16	Gritstone bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+51.8K sh	—	—	51,800
2023-06-06	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2022-08-12	Epizyme, Inc.D Disposition to Issuer	See Remarks	DDisposition to Issuer	−107K sh	—	—	0
2022-08-12	Epizyme, Inc.D Disposition to Issuer	See Remarks	DDisposition to Issuer	−179K sh	—	—	107,292
2022-08-09	Epizyme, Inc.Stock Option (Right to Buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−43.5K sh	—	—	400,000
2022-08-09	Epizyme, Inc.Stock Option (Right to Buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−56.5K sh	—	—	443,473
2022-08-09	Epizyme, Inc.F Tax Payment	See Remarks	FTax Payment	−373K sh	$1.39	−$519K	285,562
2022-08-09	Epizyme, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+400K sh	$1.39	+$556K	658,716
2022-08-09	Epizyme, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+43.5K sh	$1.39	+$60.4K	258,716
2022-08-09	Epizyme, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+56.5K sh	$1.39	+$78.6K	215,243
2022-08-09	Epizyme, Inc.Stock Option (Right to Buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−400K sh	—	—	0
2022-06-17	Gritstone bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+19K sh	—	—	19,000
2022-06-09	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+11.9K sh	—	—	11,893
2022-06-09	FATEFATE THERAPEUTICS INCA Award	Director	AAward	+8,650 sh	—	—	10,490
2022-06-07	FATEFATE THERAPEUTICS INCS Sale	Director	SSale	−841 sh	$21.89	−$18.4K	1,840
2022-06-03	FATEFATE THERAPEUTICS INCS Sale	Director	SSale	0 sh	—	—	2,681
2022-06-03	FATEFATE THERAPEUTICS INCS Sale	Director	SSale	−807 sh	$22.80	−$18.4K	1,874
2022-03-17	Epizyme, Inc.Stock Option (Right to Buy)A Award	See Remarks	AAward	+500K sh	—	—	500,000
2022-02-28	Epizyme, Inc.A Award	See Remarks	AAward	+2,331 sh	$1.27	+$2,952.212	158,716
2022-02-07	Epizyme, Inc.S Sale	See Remarks	SSale	−1,058 sh	$1.50	−$1,587	156,385
2022-02-02	Epizyme, Inc.S Sale	See Remarks	SSale	−2,639 sh	$1.37	−$3,615.43	157,443
2022-01-26	Epizyme, Inc.S Sale	See Remarks	SSale	−2,922 sh	$2.02	−$5,902.44	160,082
2021-12-06	Epizyme, Inc.S Sale	See Remarks	SSale	−1,780 sh	$2.93	−$5,215.4	163,004
2021-08-16	Epizyme, Inc.Stock Option (Right to Buy)A Award	See Remarks	AAward	+282K sh	—	—	282,270
2021-08-16	Epizyme, Inc.A Award	See Remarks	AAward	+59.2K sh	—	—	163,507
2021-06-18	Gritstone bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+937 sh	—	—	937
2021-06-02	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+4,334 sh	—	—	4,334
2021-06-02	FATEFATE THERAPEUTICS INCA Award	Director	AAward	+2,681 sh	—	—	2,681
2021-06-01	Gritstone bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+38K sh	—	—	38,000
2021-02-04	Epizyme, Inc.S Sale	See Remarks	SSale	−969 sh	$11.21	−$10.9K	104,341
2021-02-01	Epizyme, Inc.A Award	See Remarks	AAward	+29.6K sh	—	—	105,310
2021-02-01	Epizyme, Inc.Stock Option (Right to Buy)A Award	See Remarks	AAward	+141K sh	—	—	141,135
2021-01-25	Epizyme, Inc.S Sale	See Remarks	SSale	−2,872 sh	$11.41	−$32.8K	75,727
2020-12-03	Epizyme, Inc.S Sale	See Remarks	SSale	−2,522 sh	$13.54	−$34.1K	76,089
2020-06-26	Epizyme, Inc.S Sale	See Remarks	SSale	−1,805 sh	$16.15	−$29.2K	78,611
2020-06-25	Epizyme, Inc.A Award	See Remarks	AAward	+6,000 sh	—	—	80,416
2020-05-01	FATEFATE THERAPEUTICS INC · Stock Option (right to buy)A Award	Director	AAward	+16K sh	—	—	16,000
2020-03-25	Epizyme, Inc.S Sale	See Remarks	SSale	−1,243 sh	$15.28	−$19K	71,991
2020-03-24	Epizyme, Inc.A Award	See Remarks	AAward	+4,000 sh	—	—	74,416
2020-03-24	Epizyme, Inc.A Award	See Remarks	AAward	+1,575 sh	—	—	73,234
2020-02-03	Epizyme, Inc.A Award	See Remarks	AAward	+12.9K sh	—	—	71,659

Recent filings

Accepted (ET)
Jun 154
Agarwal Shefali0001193125-26-271079
SEC(opens sec.gov)
May 304
Agarwal Shefali0000950170-25-079710
SEC(opens sec.gov)
Apr 84
Agarwal Shefali0001415889-25-010436
SEC(opens sec.gov)
Jun 204
Agarwal Shefali0001415889-24-017711
SEC(opens sec.gov)
Jun 114
Agarwal Shefali0000950170-24-071948
SEC(opens sec.gov)
Jun 214
Agarwal Shefali0000899243-23-016152
SEC(opens sec.gov)
Jun 74
Agarwal Shefali0001209191-23-035039
SEC(opens sec.gov)
Aug 164
Agarwal Shefali0000899243-22-028867
SEC(opens sec.gov)
Aug 114
Agarwal Shefali0000899243-22-028419
SEC(opens sec.gov)

Companies

Address

C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE

SAN DIEGO, CA, 92131